Note 12 - Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

Notes Tables

Segment Reporting [Table Text Block]

	Three Months Ended March 31,
	2026			2025
Revenue	$	39,227		$	20,876
Less:
Research and development
External program costs:
Norovirus program		48			1,556
COVID-19 program		20,393			15,718
Other programs		—			306
Preclinical research		81			399
Process Development		—			46
Internal research and development costs		8,891			12,719
General and administrative		4,641			5,067
Interest income		(551	)		(437	)
Non-cash interest expense related to sale of future royalties		505			997
Other segment items(A)		11			1
Provision for income taxes		29			95
Segment net income (loss)	$	5,179		$	(15,591	)
Reconciliation of net income (loss)
Adjustments and reconciling items		—			—
Net income (loss)	$	5,179		$	(15,591	)